J. W. Bijlsma, F. Berenbaum, and F. P. Lafeber, Osteoarthritis: an update with relevance for clinical practice, Lancet, vol.377, pp.2115-2141, 2011.

F. M. Cicuttini and A. E. Wluka, Osteoarthritis: is oa a mechanical or systemic disease?, Nat Rev Rheumatol, vol.10, pp.515-521, 2014.

Y. Pers, M. Ruiz, D. Noel, and C. Jorgensen, Mesenchymal stem cells for the management of inflammation in osteoarthritis: state of the art and perspectives, Osteoarthritis Cartilage, vol.23, pp.2027-2062, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01834450

J. Danesh, J. G. Wheeler, G. M. Hirschfield, S. Eda, G. Eiriksdottir et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N Engl J Med, vol.350, pp.1387-97, 2004.

V. Gkretsi, T. Simopoulou, and A. Tsezou, Lipid metabolism and osteoarthritis: lessons from atherosclerosis, Prog Lipid Res, vol.50, pp.133-173, 2011.

A. Tyndall, Mesenchymal stem cell treatments in rheumatology: a glass half full?, Nat Rev Rheumatol, vol.10, issue.2, pp.117-141, 2014.

M. Krampera, G. S. Dyson, J. Scott, D. Laylor, R. Simpson et al., Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide, Blood, vol.101, pp.3722-3751, 2003.

F. Schena, C. Gambini, A. Gregorio, M. Mosconi, D. Reverberi et al., Interferon-gamma-dependent inhibition of b cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus, Arthritis Rheum, vol.62, pp.2776-86, 2010.

G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari et al., Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin e2, Blood, vol.111, pp.1327-1360, 2008.

F. Djouad, L. Charbonnier, C. Bouffi, P. Louis-plence, C. Bony et al., Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism, Stem Cells, vol.25, pp.2025-2057, 2007.

L. Kurte, M. Bravo-alegria, J. Contreras, R. Nova-lamperti, E. Tejedor et al., Mesenchymal stem cells generate a cd4+cd25+foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells, Stem Cell Res Ther, vol.4, p.65, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00836318

I. Muller, S. Kordowich, C. Holzwarth, G. Isensee, P. Lang et al., Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation, Blood Cells Mol Dis, vol.40, pp.25-32, 2008.

V. K. Prasad, K. G. Lucas, G. I. Kleiner, J. A. Talano, D. Jacobsohn et al., Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study, Biol Blood Marrow Transplant, vol.17, pp.534-575, 2011.

P. Kebriaei, L. Isola, E. Bahceci, K. Holland, S. Rowley et al., Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease, Biol Blood Marrow Transplant, vol.15, pp.804-815, 2009.

L. Blanc, K. Frassoni, F. Ball, L. Locatelli, F. Roelofs et al., Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase 2 study, Lancet, vol.371, pp.1579-86, 2008.

L. Sun, D. Wang, J. Liang, H. Zhang, X. Feng et al., Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus, Arthritis Rheum, vol.62, pp.2467-75, 2010.

F. Carrion, N. E. Ruiz, C. Diaz, F. Inostroza, C. Rojo et al., Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients, Lupus, vol.19, pp.317-339, 2010.

R. Ciccocioppo, M. E. Bernardo, A. Sgarella, R. Maccario, M. A. Avanzini et al., Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising crohn's disease, Gut, vol.60, pp.788-98, 2011.

M. Duijvestein, A. C. Vos, H. Roelofs, M. E. Wildenberg, B. B. Wendrich et al., Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal crohn's disease: results of a phase 1 study, Gut, vol.59, pp.1662-69, 2010.

D. Mougiakakos, R. Jitschin, C. C. Johansson, R. Okita, R. Kiessling et al., The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory t cells by human mesenchymal stem cells, Blood, vol.117, pp.4826-4861, 2011.

Y. Pers and C. Jorgensen, Adipose derived stem cells for regenerative therapy in osteoarticular diseases, Horm Mol Biol Clin Investig, vol.28, issue.3, pp.113-133, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01834269

Y. Pers, L. Rackwitz, R. Ferreira, O. Pullig, C. Delfour et al., Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase 1 dose-escalation trial, Stem Cells Transl Med, vol.5, issue.7, pp.847-56, 2016.

A. Bura, V. Planat-benard, P. Bourin, J. Silvestre, F. Gross et al., Phase 1 trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia, Cytotherapy, vol.16, pp.245-57, 2014.

N. Bellamy, W. W. Buchanan, C. H. Goldsmith, J. Campbell, and L. W. Stitt, Validation study of womac: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee, J Rheumatol, vol.15, pp.1833-1873, 1988.

T. Pham, D. Van-der-heijde, R. D. Altman, J. J. Anderson, N. Bellamy et al., Omeract-oarsi initiative: osteoarthritis research society international set of responder criteria for osteoarthritis clinical trials revisited, Osteoarthritis Cartilage, vol.12, pp.389-99, 2004.

J. J. Van-dongen and A. Orfao, EuroFlow: resetting leukemia and lymphoma immunophenotyping basis for companion diagnostics and personalized medicine, Leukemia, vol.26, pp.1899-907, 2012.

H. T. Maecker, J. P. Mccoy, and R. Nussenblatt, Standardizing immunophenotyping for the human immunology project, Nat Rev Immunol, vol.12, pp.191-200, 2012.

M. Hasan, B. Beitz, V. Rouilly, V. Libri, A. Urrutia et al., Semi-automated and standardized cytometric procedures for multi-panel and multi-parametric whole blood immunophenotyping, Clin Immunol, vol.157, pp.261-76, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-01380961

B. K. Stansfield and D. A. Ingram, Clinical significance of monocyte heterogeneity, Clin Transl Med, vol.4, p.5, 2015.

P. A. Blair, L. Y. Norena, F. Flores-borja, D. J. Rawlings, D. A. Isenberg et al., cd19(+)cd24(hi)cd38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients, Immunity, vol.32, pp.129-169, 2010.

A. E. Coutinho and K. E. Chapman, The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights, Mol Cell Endocrinol, vol.335, pp.2-13, 2011.

K. L. Winthrop, The emerging safety profile of jak inhibitors in rheumatic disease, Nat Rev Rheumatol, vol.13, pp.234-277, 2017.

C. M. Peeters, M. J. Leijs, M. Reijman, G. J. Van-osch, and P. K. Bos, Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review, Osteoarthritis Cartilage, vol.21, pp.1465-73, 2013.

M. Najar, G. Raicevic, H. Fayyad-kazan, D. Bron, M. Toungouz et al., Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells, Cytotherapy, vol.18, pp.160-71, 2016.

L. Blanc, K. Rasmusson, I. Sundberg, B. Gotherstrom, C. Hassan et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, vol.363, pp.1439-1480, 2004.

R. Jitschin, D. Mougiakakos, V. Bahr, L. Volkl, S. Moll et al., Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation, Stem Cells, vol.31, pp.1715-1740, 2013.

E. Dander, G. Lucchini, P. Vinci, M. Introna, F. Masciocchi et al., Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring, Leukemia, vol.26, pp.1681-84, 2012.

K. Zhao, R. Lou, F. Huang, Y. Peng, Z. Jiang et al., Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, vol.21, pp.97-104, 2015.

M. Belghith, J. A. Bluestone, S. Barriot, J. Megret, J. Bach et al., Tgf-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to cd3 in overt autoimmune diabetes, Nat Med, vol.9, pp.1202-1208, 2003.

A. Kukreja, G. Cost, J. Marker, C. Zhang, Z. Sun et al., Multiple immuno-regulatory defects in type-1 diabetes, J Clin Invest, vol.109, pp.131-171, 2002.

T. Morita, Y. Shima, J. B. Wing, S. Sakaguchi, A. Ogata et al., The proportion of regulatory t cells in patients with rheumatoid arthritis: a meta-analysis, PLoS One, vol.11, p.162306, 2016.

S. Gao, B. Hao, X. F. Yang, and W. Q. Chen, Decreased cd200r expression on monocyte-derived macrophages correlates with th17/treg imbalance and disease activity in rheumatoid arthritis patients, Inflamm Res, vol.63, pp.441-50, 2014.

J. Kim, C. Kim, S. Ha, and J. , Subpopulations of regulatory t cells in rheumatoid arthritis, systemic lupus erythematosus, and behcet's disease, J Korean Med Sci, vol.27, pp.1009-1022, 2012.

M. R. Ehrenstein, J. G. Evans, A. Singh, S. Moore, G. Warnes et al., Compromised function of regulatory t cells in rheumatoid arthritis and reversal by anti-tnf alpha therapy, J Exp Med, vol.200, pp.277-85, 2004.

M. Streitz, T. Miloud, M. Kapinsky, M. R. Reed, R. Magari et al., Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the one study, Transplant Res, vol.2, p.17, 2013.

Y. Peng, X. Chen, Q. Liu, X. Zhang, K. Huang et al., Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of cd5+ regulatory b cells producing interleukin 10, Leukemia, vol.29, pp.636-682, 2015.

M. Tsukamoto, N. Seta, K. Yoshimoto, K. Suzuki, K. Yamaoka et al., Cd14(bright)cd16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis, Arthritis Res Ther, vol.19, p.28, 2017.

M. Rossol, S. Kraus, M. Pierer, C. Baerwald, and U. Wagner, The cd14(bright)cd16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the th17 cell population, Arthritis Rheum, vol.64, pp.671-77, 2012.

D. Loukov, S. Karampatos, M. R. Maly, and D. Bowdish, Monocyte activation is elevated in women with knee-osteoarthritis and associated with inflammation, bmi and pain, Osteoarthritis Cartilage, vol.26, pp.255-63, 2018.

C. P. Verschoor, J. Johnstone, J. Millar, R. Parsons, A. Lelic et al., Alterations to the frequency and function of peripheral blood monocytes and associations with chronic disease in the advanced-age, frail elderly, PLoS One, vol.9, p.104522, 2014.